4to Seminario Internacional y 4to Taller Nacional "Uso y desarrollo de productos de la industria isotópica para la salud"

Luis Ducat Pagés

Resumen

El trabajo presenta una reseña científica de los principales temas abordados en el 4to Seminario Internacional y 4to Taller Nacional "Uso y Desarrollo de Productos de la Industria Isotópica para la Salud" celebrado los días 7, 8 y 9 de diciembre de 2010 en conmemoración al XV Aniversario del Centro de Isótopos.

Palabras clave

medicina nuclear, radioinmunología, radioinmunoescintigrafía, radiofármacos, radioinmunoterapia, linfomas, radisótopos, radiofármacos, precisión

Texto completo:

PDF Epub HTML

Referencias

Cyclotron produced radionuclides: principles and practice. Technical Reports Series no. 465. Vienna: International Atomic Energy Agency, 2008.

Appropriate use of fdg-pet for the management of cancer patients. IAEA Human Health Series no. 9. Vienna: International Atomic Energy Agency, 2010.

WAGNER HN Jr. Molecular Imaging: Thriving All Over the World. J Nucl. Med. 2007; 48(8): 15N-16N, 19N-38N.

STORTO G, NICOLAI E, SALVATORE M. 18F-FDG-PET/CT for early monitoring of tumor response. J Nucl Med Mol Imag. 2009; 53: 167-180

RAY G, BAIDOO K, WONG K, et. al. Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. British J Pharmacol. 2009; 157(8): 1541-1548.

GOLDSMITH SJ, SIGNORE A. An overview of the diagnostic and therapeutic use of monoclonal antibodies in medicine. Q.J. Nucl. Med. Mol. Imaging. 2010; 54(6): 574-81.

GOVINDAN SV, GOLDENBERG DM. New antibody conjugates in cancer therapy. The Scientific World Journal. 2010; 10: 2070-2089

CASACÓ A, LÓPEZ G, GARCÍA I, et. al. Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188Re in adult recurrent high-grade glioma. Canc. Biol. Ther. 2008; 7(3): 333-339.

LIN FI, IAGARU A. Current concepts and future directions in radioimmunotherapy. Curr Drug Discov Technol. 2010; 7(4): 253-62.

REICHERT JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011, 3(1): 76-99.

KAMATH S, BUOLAMWINI JK. Targeting egfr and her-2 receptortyrosine kinases for cancer drug discovery and development. Med Res Rev. 2006; 26(5): 569-594.